Trial Profile
Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine SB732462 in HIV Infected Subjects Aged 18 to 55 Years Old
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 732461 (Primary) ; AS01B
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 18 Oct 2013 Results published in Vaccine.
- 07 Feb 2012 New profile created for NCT01092611 (213081). This appears to be a follow-up of more than one study. NCT00814762 was conducted only in Germany and enrolled 41 patients while the extension is enrolling 215.
- 02 Mar 2011 Status changed from recruiting to completed for the randomised part of the study.